Baxter/$BAX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Baxter
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Ticker
$BAX
Sector
Primary listing
NYSE
Employees
38,000
Headquarters
Website
Baxter Metrics
BasicAdvanced
$9.6B
-
-$0.66
0.61
$0.68
3.64%
Price and volume
Market cap
$9.6B
Beta
0.61
52-week high
$37.74
52-week low
$17.47
Average daily volume
7.6M
Dividend rate
$0.68
Financial strength
Current ratio
1.837
Quick ratio
0.954
Long term debt to equity
124.161
Total debt to equity
134.627
Interest coverage (TTM)
3.23%
Profitability
EBITDA (TTM)
2,074
Gross margin (TTM)
37.93%
Net profit margin (TTM)
-3.09%
Operating margin (TTM)
9.86%
Effective tax rate (TTM)
-30.74%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
2.85%
Return on equity (TTM)
-4.66%
Valuation
Price to revenue (TTM)
0.87
Price to book
1.31
Price to tangible book (TTM)
-3.17
Price to free cash flow (TTM)
41.709
Free cash flow yield (TTM)
2.40%
Free cash flow per share (TTM)
0.448
Dividend yield (TTM)
3.64%
Forward dividend yield
3.64%
Growth
Revenue change (TTM)
3.90%
Earnings per share change (TTM)
-422.68%
3-year revenue growth (CAGR)
-8.26%
10-year revenue growth (CAGR)
0.82%
3-year earnings per share growth (CAGR)
-48.04%
10-year earnings per share growth (CAGR)
-14.09%
3-year dividend per share growth (CAGR)
-15.82%
10-year dividend per share growth (CAGR)
-8.62%
What the Analysts think about Baxter
Analyst ratings (Buy, Hold, Sell) for Baxter stock.
Bulls say / Bears say
Baxter has fully restocked its IV solutions inventory and removed all supply restrictions at its North Cove, NC facility, demonstrating a rapid operational rebound from the disruptions caused by Hurricane Helene.
On July 7, 2025, Baxter named Andrew Hider as its new president and CEO; his 25 years of leadership experience at ATS and Danaher are expected to boost strategic execution and support growth initiatives.
New CEO Andrew Hider pointed to strong global demand for intravenous solutions after restocking in the wake of Hurricane Helene, underscoring the company’s resilience in its core infusion therapies business.
Baxter reduced its 2025 adjusted earnings guidance to $2.42–$2.52 per share, compared to the previous $2.47–$2.55, after it reported Q2 revenue of $2.81 billion and fell short of analysts’ profit expectations due to ongoing effects from Hurricane Helene on IV solutions demand.
The company voluntarily stopped shipping its Novum IQ Large Volume Pump following two reported deaths and other safety incidents, which has increased regulatory scrutiny and reputational risk.
S&P Global Ratings downgraded Baxter to BBB– on November 7, 2025, citing underperformance in core areas, a slower-than-expected recovery in IV therapies, and rising leverage, highlighting the company’s financial risk due to weak operational results.
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2025.
Baxter Financial Performance
Revenues and expenses
Baxter Earnings Performance
Company profitability
Baxter News
AllArticlesVideos
Class Action Lawsuit Filed: Baxter International, Inc. (BAX) - Join by December 15, 2025 - Contact Levi & Korsinsky
Newsfile Corp8 hours ago
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
Newsfile Corp21 hours ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Newsfile Corp21 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Baxter stock?
Baxter (BAX) has a market cap of $9.6B as of November 13, 2025.
What is the P/E ratio for Baxter stock?
The price to earnings (P/E) ratio for Baxter (BAX) stock is 0 as of November 13, 2025.
Does Baxter stock pay dividends?
Yes, the Baxter (BAX) stock pays dividends to shareholders. As of November 13, 2025, the dividend rate is $0.68 and the yield is 3.64%. Baxter has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Baxter dividend payment date?
The next Baxter (BAX) dividend payment is scheduled for January 02, 2026.
What is the beta indicator for Baxter?
Baxter (BAX) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.